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Abstract Subcutaneous IgG treatment for primary immuno-
deficiencies (PI) is particularly well suited for children because
it does not require venous access and is mostly free of systemic
adverse events (AEs). In a prospective, open-label, multicenter,
single-arm, Phase III study, 18 children and five adolescents
with PI were switched from previous intravenous (IVIG) or
subcutaneous (SCIG) IgG treatment to receive dose-equivalent,
weekly subcutaneous infusions of Hizentra
® for 40 weeks.
MeanIgGtroughlevelsweremaintainedinpatientspreviously
on SCIG, or increased in those previously on IVIG, regardless
of age. No seriousbacterial infections were reportedduring the
efficacyperiodofthestudy.Theratesofnon-seriousinfections
were 4.77 (children) and 5.18 (adolescents) infections per
patient per year. Related AEs were observed in seven children
(38.9%) and two adolescents (40%). Three serious AEs and
two AEs leading to discontinuation (all unrelated) were
reported in children. Hizentra
® is an effective and well-
tolerated treatment for pediatric patients.
Keywords Subcutaneous immunoglobulin (SCIG).
primary immunodeficiency.local tolerability.serum IgG
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Introduction
Primary immunodeficiency (PI) disorders, such as common
variable immunodeficiency (CVID) and X-linked agamma-
globulinemia (XLA), are often diagnosed in childhood and
require life-long replacement therapy with intravenous
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DOI 10.1007/s10875-011-9557-z(IVIG) or subcutaneous (SCIG) IgG [1–5]. Patients with PI
are predisposed to recurrent respiratory, skin, or gastroin-
testinal infections that may lead to chronic damage. IgG
replacement is an effective therapy, usually administered
intravenously [6–12]. Subcutaneous IgG administration,
which is an increasingly widely used alternative, is particu-
larly suitable for children, as it does not require venous
access and is mostly free of systemic adverse events (AEs)
[13–17]. Moreover, compared to adults, children require
lower volumes for the infusion of prescribed doses, which
makes them well suited for SCIG therapy.
Therapy with the newly developed, highly concentrated
SCIG products can be easily integrated into daily activities,
thus offering patients more flexibility. Hizentra
® (IgPro20,
approved in the USA in March 2010) is a new 20% liquid
formulation with stability at 25°C for at least 24 months,
which has high purity and proven pathogen safety [18–20].
Hizentra
® can be administered at relatively high infusion
rates, which, together with low infusion volumes, contributes
to potentially short infusion times.
In this prospective, open-label, multicenter, single-arm,
Phase III study (NCT00542997), the efficacy and tolerability
of Hizentra
® were evaluated in patients switched from
previous IVIG or SCIG therapy at equivalent doses [21].
The rationale for using SCIG doses equivalent to previous
IVIG or SCIG dosing was based on the European experience
showing that SCIG administered at doses equivalent to IVIG
is sufficient to achieve comparable IgG trough levels in
patients with PI. This approach is reflected in the European
Medicines Agency requirement to show that equivalent
serum IgG levels can be achieved with the same doses
[22]. Here we report efficacy and safety results in pediatric
patients in comparison with adults.
Patients and Methods
Patients
Eighteen children (2–11 years) and five adolescents (12–
15 years) with CVID, XLA, or autosomal recessive
agammaglobulinemia were enrolled in the study. Major
inclusion criteria were stable IVIG therapy at regular 3- or
4-week intervals or weekly SCIG therapy for at least
6 months before study start, at a monthly dose of 0.2 to
0.8 g/kg body weight (bw), and at least three documented
serum IgG trough levels of ≥5 g/L. Patients who had never
been treated with immunoglobulin replacement therapy
were excluded from the study. Patients were also excluded
if they had any condition that was likely to interfere with
evaluation of the study medication or satisfactory conduct
of the study. Detailed description of inclusion and exclusion
criteria is given elsewhere [21].
This study was conducted in accordance with the Interna-
tional Conference on Harmonization Good Clinical Practice
guidelines and the Declaration of Helsinki. The study
protocol and all other study-related documents were
reviewed and approved by the appropriate local Independent
Ethics Committees. Written informed consent was obtained
from all patients or patients’ parents or legal guardians.
Study Design
This was a prospective, open-label, multicenter, single-arm,
Phase III study with a 12-week wash-in/wash-out period
followed by a 28-week efficacy period [21]. A pharmaco-
kinetic (PK) substudy was conducted in week 28±1, in
which nine children and three adolescents participated.
The primary objective of this study was to show that
sustained serum IgG levels can be achieved with IgG doses
comparable to previous IgG treatment. Individual IgG
doses were equivalent to previous IVIG or SCIG doses,
with weekly administrations. Dose adjustments were made
in the wash-in/wash-out period in case IgG trough levels
were <5 g/L.
Premedication prior to infusion for alleviating AEs was
not allowed. Oral and parenteral steroids were allowed if
the average daily dose was <0.15 mg of prednisone
equivalent per kilogram per day. Local anesthetics could
be used before infusion to reduce the pain associated with
needle insertion if required.
Hizentra
® was administered subcutaneously using infu-
sion pumps in sites on the abdomen, thighs, and/or lateral
hip [21]. Infusion techniques varied according to local
practice and patients already on SCIG treatment continued
with their established infusion technique. The maximal
volume per injection site was limited to 25 mL. The
infusion rate per site was not to exceed 35 mL/h during the
efficacy period, depending on tolerability. Several infusions
were performed under supervision at the study site, the rest
were administered at home by the patient or patient’s
parent/guardian.
Efficacy and Safety Assessments
The primary efficacy objective was achievement of IgG
trough levels at six consecutive weeks at steady state
(Infusions 12 to 17) similar to three pre-study IgG trough
levels (during the last 3 to 6 months prior to the study).
Trough serum IgG levels were measured before Infusions 1,
4, 8, 12–17, 20, and every fourth infusion thereafter.
Secondary efficacy endpoints included rate of clinically
documented serious bacterial infections (SBIs), number of
infection episodes, number of days missed from school/day
care or unable to perform normal activities due to infections
(abbreviated further as number of days missed from school/
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infections, and use of antibiotics for infection prophylaxis
or treatment. SBIs (bacterial pneumonia, bacteremia/septi-
cemia, osteomyelitis/septic arthritis, bacterial meningitis,
and visceral abscess) were diagnosed using pre-defined
criteria adjusted to both adult and pediatric patients [23].
Non-serious infections were diagnosed at the discretion of
the Investigators according to the national standard of
medical practice.
MaximalserumIgGconcentration(Cmax), time to reaching
Cmax (Tmax), and area under the concentration/time curve
(AUC) until the last measured concentration were evaluated.
Blood samples for IgG determination were taken before
Infusion 28, 10±5 min prior to end of infusion, 2±1 h after
infusion, and after 1, 2, 3, 4, and 7 days.
Information about AEs was collected continuously.
Patients or their guardians documented any findings in
patient diaries and Investigators evaluated them at visits.
For the analysis of local reactions, 25 preferred terms of the
category “General disorders and administration site con-
ditions” were combined in the category of local reactions.
Local tolerability was assessed by the patients within 24 to
72 h after infusion and reviewed by the investigator during
visits. Standard hematology, serum chemistry, and urinaly-
sis laboratory parameters were determined at screening,
before Infusions 1, 4, 28, and at the completion visit.
Statistical Methodology
Efficacy analyses were carried out on the intent-to-treat
(ITT) population (17 children, five adolescents, and 24
adults) defined as all patients who were treated with
Hizentra
® during the efficacy period (starting from
week 13). Safety analyses were carried out on the all-
treated population (18 children and five adolescents)
defined as all patients who were treated with Hizentra
®
during any study period. PK analyses were carried out on
the per-protocol pharmacokinetic population (nine children
and three adolescents) comprising all patients who had
received uniformly repeated weekly doses of Hizentra
® at
least 12 weeks before week 28±1, with not more than three
missing samples or outliers in the AUC sampling period.
For primary efficacy analyses, six consecutive steady-
state IgG trough values were aggregated to the patient’s
median value. The same procedure was used for the three
most recent IgG trough values ≥5 g/L from the previous
treatment [21]. A post hoc analysis with point estimates and
a two-sided 95% confidence interval (CI) for the change
from pre-study serum IgG levels was performed using the
Hodges–Lehmann nonparametric analysis.
The rate of SBIs per patient per year was estimated with a
99% upper confidencelimit (CL),and the numberofinfection
episodes was estimated with a two-sided 95% CI. Other
secondary endpoints were summarized with descriptive
statistics. AUC was obtained by the trapezoidal rule between
the first and last IgG measurement, ignoring outliers.
Adverse events were coded using the Medical Dictionary
for Regulatory Activities (MedDRA), version 12.0. Tem-
porally associated AEs were defined as occurring between
the start of infusion and 72 h after the end of infusion.
Results
Patients
All 23 pediatric patients screened were enrolled in the
study. Two of these discontinued due to unrelated adverse
events (after week 2 and after week 36). The remaining 21
pediatric patients completed the study. Of 28 adults
enrolled, 22 completed the study.
The proportion of females among children was three
times lower than that of males (Table I), due to the high
proportion of patients with XLA (all males).
Study Drug Administration
All patients in the ITT population received the intended 12
infusions during the wash-in/wash-out period. Most
patients received the planned 40 infusions during the study:
16 children (94%), five adolescents (80%), and 17 (71%)
adults. Five adults (21%) received 41 infusions.
The mean (SD) of individual median Hizentra
® doses per
week for the entire study period was 129.9 (46.2) mg/kg bw
in children (range, 76–262 mg/kg bw) and 113.7 (28.0) mg/
kg bw in adolescents (range, 72–150 mg/kg bw), both very
similar to the dose of 114.3 (27.6) mg/kg bw administered
in adults (range, 59–189 mg/kg bw).
Dose increases of >10% of the planned dose were made in
four children and one adolescent during the wash-in/wash-out
period. One child and one adolescent had dose decreases
of >10%. Dose adjustments in adults were not necessary.
The mean of the individual median infusion rates was
lower in children (19.0 mL/h) compared to adolescents and
adults (31.2 and 28.5 mL/h, respectively). The median
duration of infusion per week was 0.78 h (range, 0.3–2.5 h)
in children and 1.0 h (range, 0.5–2.5 h) in adolescents, which
was lower than that in adults (1.42 h; range, 0.7–3.3 h)
because of the higher total dose administered in adults.
Efficacy
Primary Efficacy Endpoint
The study objective was met: Hizentra
® treatment resulted
in serum IgG trough levels comparable to or higher than
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individual pre-study median IgG trough level in children
was 6.94 g/L, and in adolescents, 7.99 g/L compared with
7.81 g/L in adults (Table III). The mean of the individual
median IgG trough levels measured before Infusions 12 to
17 were 7.86 g/L in children, and 7.91 g/L in adolescents
compared with 8.31 g/L in adults, suggesting that IgG
levels were maintained in all age groups.
Children achieved the largest increase in mean of the
individual median IgG trough levels from baseline to study
end (13.3%), while the change in adolescents and adults
was small (Fig. 1). Most likely, this observation was due to
the fact that two thirds of the children (n=11) had been
treated with IVIG prior to the study and had a pre-study
IgG trough level of 6.47 g/L (mean of individual medians).
The IgG trough level measured before Infusions 12 to 17 in
these children was 7.92 g/L (mean of individual medians),
which corresponded to an increase of 22.4%. In compari-
son, the pre-study IgG trough level in children previously
treated with SCIG (n=6, mean of individual medians
7.80 g/L) was similar to the level achieved with Hizentra
®.
The four adolescents who had previously been on SCIG
had a pre-study IgG trough level of 8.65 g/L (mean of
individual medians). Adults previously treated with IVIG
had a larger increase in IgG levels (n=13, from 7.15 to
8.14 g/L) compared with those previously on SCIG (n=9,
from 8.76 to 8.56 g/L), similarly to children.
A post hoc statistical analysis of the change from
baseline in serum IgG trough levels confirmed that IgG
levels were maintained in adolescents and adults, and
increased in children. For the efficacy period of the study
(Infusions 12–17), the mean change from baseline in IgG
levels was most pronounced in children (0.920 g/L), with a
Hodges–Lehmann point estimate for the change from
baseline of 0.680 g/L. The two-sided 95% CI for this
change (0.030, 1.500) suggested a significant difference in
IgG levels from pre-study level to the level achieved during
the efficacy period. The corresponding change from
baseline in adolescents and adults indicated stable IgG
levels and no significant difference from pre-study to study
IgG levels (Table III). Similar results were obtained for the
entire study period (Infusions 12–41). A significant
increase in IgG levels from baseline was observed in
children, while the IgG levels in the other age groups
remained stable (Table III).
Fig. 1 Individual median serum IgG trough levels before and during
the study. Median values were calculated for each patient for pre-study
IgG levels and IgG levels measured before Infusions 12 to 17 (efficacy
period; primary efficacy endpoint) and before Infusions 12 to 41
(entire study period)
Characteristic Children Adolescents Adults
2–11 years 12–15 years 16–64 years
N=18 N=5 N=28
Gender, n (%)
Female 5 (27.8) 0 (0) 11 (39.3)
Male 13 (72.2) 5 (100) 17 (60.7)
Age (years)
Mean (SD) 7.2 (2.5) 14.0 (1.0) 34.1 (12.7)
Median (Range) 7.5 (3–11) 14.0 (13–15) 32.5 (16–60)
Weight (kg)
Mean (SD) 25.9 (11.06) 57.1 (15.84) 69.2 (13.34)
Median (Range) 22.0 (13–56) 53.3 (36–77) 70.2 (41–96)
BMI (kg/m
2)
Mean (SD) 16.4 (2.88) 20.6 (2.29) 23.3 (3.96)
Median (Range) 15.3 (12–24) 20.1 (18–23) 23.0 (16–32)
Primary disease
CVID, n (%) 7 (38.9) 0 (0) 23 (82.1)
XLA, n (%) 10 (55.6) 5 (100) 5 (17.9)
ARAG, n (%) 1 (5.6) 0 (0) 0 (0)
Table I Demographic and
baseline characteristics
(AT population)
AT all treated (23 pediatric
patients), N number of patients
in age group, SD standard
deviation, CVID common
variable immunodeficiency, XLA
X-linked agammaglobulinemia,
ARAG autosomal recessive
agammaglobulinemia
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the seven pediatric patients who had dose adjustments, no
relevant difference was observed compared to the analysis
for the ITT population.
Pharmacokinetic Parameters
Nine children and three adolescents participated in the PK
substudy. There were no clinically relevant differences
between children, adolescents, and adults (n=11) in the
PK parameters for serum IgG.
In children, slightly lower mean values compared to
adults were observed for Cmax (8.09 vs. 8.31 g/L) and AUC
(52.30 vs. 54.52 day×g/L), which was in agreement with
the slightly lower mean IgG trough concentrations in
children. Corresponding values in adolescents were similar
to those in adults (Table II).
Secondary Efficacy Endpoints
Hizentra
® was effective in maintaining the rate of infections
at a very low level. No SBIs were reported during the
efficacy period of the study (Table III). A child with a
history of recurrent severe pneumonia experienced an SBI
of pneumonia during the wash-in/wash-out period.
Although the annual rate of all infections (including
SBIs) in children was slightly lower than in adults (4.77 vs.
5.47 infections per patient per year; Table III), no age-
related trends in the incidence of specific types of infection
were observed. The most frequent type of infection was
cough (seven events in children and six events in
adolescents), followed by upper respiratory tract infection
(eight events in children and two events in adolescents) and
bronchitis (four events in children only).
Eight children missed 139 days from school/day care
and three children spent a total of 78 days in hospital
(Table III). Of these, the child with recurrent pneumonia
missed 71 days from school and spent 63 days in hospital.
This child’s experience differed substantially from that of
the other patients in the study, regardless of age. Therefore,
a post hoc analysis excluding this child was performed to
evaluate the efficacy in patients with less severe disease
(Table III). In comparison, four adolescents missed only
5 days and none was hospitalized, while eight adults missed
54 days and one adult spent 8 days in hospital. Treatment
with antibiotics for prophylaxis or against infections was
prescribed to 11 children (442 days) and one adolescent
(1 day). The child with recurrent pneumonia was treated for
182 days. Excluding this child, the rate of days on
antibiotics in children was twofold lower than the one in
adults (Table III).
Safety and Tolerability
Local Reactions
Local tolerability results showed that patients tolerated
Hizentra
® administration well. Children and adolescents
experienced 27 and 7 local reactions, respectively (0.040
and 0.035 events per infusion). In children, the most
frequent local reactions were infusion site mass (five
events), infusion site pruritus (five events), and infusion
site pain (four events), followed by infusion site reaction
(three events). Adolescents experienced infusion site
pruritus (four events), infusion site swelling (two events),
and infusion site extravasation (one event). Most of the
local reactions were mild in intensity (26 events in children
and three in adolescents; Table IV). A total of four moderate
local reactions were reported, and only one was severe.
Adults reported more local reactions in general, most being
mild in intensity (67 of 76 events), yet the rates of moderate
local reactions were similar to those in pediatric patients.
Patients or their guardians evaluated the local tolerability
as “very good” or “good” for 98.5% of the infusions in
children; a rating of “fair” or “poor” was given only for five
(0.7%) and two (0.3%) infusions, respectively. In adoles-
cents, local tolerability was rated as “very good” or “good”
for 95.5% of the infusions and “fair” for nine (4.5%)
infusions. Local tolerability assessments in adults were
similar to those in pediatric patients: 95.5% of the infusions
were rated as “very good” or “good,” 4.0% as “fair,” and
0.4% as “poor.”
Table II PK parameters by age group (PPK population)
Parameter Children Adolescents Adults
2–11 years 12–15 years 16–64 years
N=9 N=3 N=11
Cmax (g/L), mean (SD) 8.09 (1.492) 8.60 (1.443) 8.31 (1.096)
Tmax (day), median (range) 2.06 (0.94–6.92) 1.98 (1.93–2.94) 2.07 (0.95–3.98)
AUC (day × g/L), mean (SD) 52.30 (9.987) 54.91 (11.548) 54.52 (8.672)
PPK per-protocol pharmacokinetic, N number of patients in age group, Cmax maximum concentration, Tmax time point of maximum concentration,
AUC area under the concentration–time curve until last measured concentration, SD standard deviation
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Efficacy endpoint Children Adolescents Adults
2–11 years 12–15 years 16–64 years
N=17 N=5 N=24
IgG trough levels
Pre-study
Mean±SD 6.94±1.223 7.99±1.946 7.81±1.666
Median (range) 6.77 (5.3–10.1) 7.88 (5.4–10.3) 7.49 (5.3–11.7)
Infusions 12–17
a, e
Mean±SD 7.86±1.720 7.91±1.432 8.31±1.250
Median (range) 7.66 (5.1–12.4) 7.54 (6.2–9.5) 8.15 (6.3–10.9)
Infusions 12–41
f
Mean±SD 7.78±1.510 8.14±1.390 8.32±1.211
Median (range) 7.67 (5.2–11.2) 7.71 (6.7–9.9) 8.25 (6.4–10.8)
SBIs
Number (%) of patients
b 0 (0) 0 (0) 0 (0)
Number of events (annual rate per patient) 0 (0) 0 (0) 0 (0)
[upper 99% CL] [0.511] [1.705] [0.376]
[0.543]
d NA NA
All infections
Number (%) of patients
b 15 (88.2) 3 (60.0) 18 (75.0)
Number of events (annual rate per patient) 43 (4.77) 14 (5.18) 67 (5.47)
40 (4.714)
d NA NA
[95% CI] [3.452; 6.426] [2.833; 8.695] [4.241; 6.949]
[3.368, 6.419]
d NA NA
Days missed from school/day care
Number (%) of patients
c 8 (47.1) 4 (80.0) 8 (33.3)
Number of days (annual rate per patient) 139 (14.90) 5 (1.79) 54 (4.28)
68 (7.74)
d NA NA
Days hospitalized due to infection
Number (%) of patients
c 3 (17.7) 0 (0) 1 (4.2)
Number of days (annual rate per patient) 78 (8.36) 0 (0) 8 (0.63)
15 (1.71)
d NA NA
Days with antibiotics for infection prophylaxis or treatment
Number (%) of patients
b 11 (64.7) 1 (20.0) 17 (70.8)
Number of days (annual rate per patient) 442 (49.04) 1 (0.37) 727 (59.38)
260 (30.64)
d NA NA
With the exception of IgG trough levels, data are for the efficacy period
ITT intent-to-treat, N number of patients in age group, SBI serious bacterial infections, CL confidence limit, CI confidence interval, NA not
applicable
aPrimary efficacy endpoint
bThe total number of days in the study was 3,290 (children), 986 (adolescents), and 4,469 (adults)
cThe total number of days from patient diaries was 3,406 (children), 1,020 (adolescents), and 4,607 (adults)
dData excluding the patient who suffered from recurrent pneumonias
eData from a post hoc nonparametric analysis of the change in IgG levels from baseline to the efficacy period (Infusions 12–17): children (mean
change from baseline, 0.920; Hodges–Lehmann point estimate, 0.680; two-sided 95% CI, 0.030, 1.500); adolescents (mean change from baseline,
−0.089; Hodges–Lehmann point estimate, −0.152; two-sided 95% CI, −0.770, 0.810); adults (mean change from baseline, 0.366; Hodges–
Lehmann point estimate, 0.377; two-sided 95% CI, −0.058, 0.838)
fData from a post hoc nonparametric analysis of the change in IgG levels from baseline to the entire study period (Infusions 12–41): children
(mean change from baseline, 0.846; Hodges–Lehmann point estimate, 0.683; two-sided 95% CI, 0.055, 1.445); adolescents (mean change from
baseline, 0.145; Hodges–Lehmann point estimate, −0.020; two-sided 95% CI, −0.370, 1.300); adults (mean change from baseline, 0.386; Hodges–
Lehmann point estimate, 0.355; two-sided 95% CI, −0.090, 0.820)
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A summary of all AEs, including local reactions, is
provided in Table V.
The rates of AEs, excluding local reactions, were similar in
all age groups: 107 AEs occurred during 678 infusions in
children (rate 0.158 AEs per infusion) and 41 AEs occurred
during 199 infusions in adolescents (rate 0.206 AEs per
infusion), compared with 269 AEs during 954 infusions in
adults(0.282AEsperinfusion).Excludinglocalreactions,the
most common AEs in children were cough and upper
respiratory tract infection (12 and 10 events, respectively;
rates 0.018 and 0.015 events per infusion); in adolescents,
cough was the most common AE (eight events, rate 0.040).
The rates of temporally associated AEs other than local
reactions were somewhat lower in pediatric patients than in
adults: 0.090 AEs per infusion in children and 0.085 AEs
per infusion in adolescents, compared with 0.148 AEs per
infusion in adults. The most common temporally associated
AEs were respiratory infections, such as cough, upper
respiratory tract infection, and bronchitis.
The frequency of related AEs was lower in children and
adolescents than in adults. Excluding local reactions, 20
related AEs were reported in children and four in
adolescents (rates 0.029 and 0.020 AEs per infusion,
respectively). Excluding local reactions and infections, the
most common related AEs in children were pruritus (six
events, rate 0.009 events per infusion), erythema (three
Local reaction Children Adolescents Adults
2–11 years 12–15 years 16–64 years
N=18 N=5 N=28
Ni=678 Ni=199 Ni=954
Total, no. of AEs (rate per infusion)
27 (0.040) 7 (0.035) 76 (0.080)
Mild local reactions, no. of AEs (rate per infusion)
Total 26 (0.038) 3 (0.015) 67 (0.070)
Moderate local reactions, no. of AEs (rate per infusion)
Total 1 (0.001) 3 (0.015) 9 (0.009)
Infusion site nodule 1 (0.001) 0 0
Infusion site pruritus 0 2 (0.010) 0
Infusion site swelling 0 1 (0.005) 1 (0.001)
Infusion site inflammation 0 0 1 (0.001)
Infusion site pain 0 0 2 (0.002)
Infusion site reaction 0 0 3 (0.003)
Infusion-related reaction 0 0 2 (0.002)
Severe local reactions, no. of AEs (rate per infusion)
Total 0 1 (0.005) 0
Infusion site pruritus 0 1 (0.005) 0
Table IV Local reactions
(AT population)
AT all treated, N number of
patients in age group, Ni number
of infusions, AEs adverse events
Table V Summary of adverse events including local reactions (AT population)
AE category Children Adolescents Adults
2–11 years 12–15 years 16–64 years
N=18 N=5 N=28
Ni=678 Ni=199 Ni=954
Patients with AEs, n (%) 18 (100) 5 (100) 27 (96.4)
Patients with related AEs, n (%) 7 (38.9) 2 (40.0) 22 (78.6)
Patients with temporally associated AEs (72 h), n (%) 17 (94.4) 5 (100) 26 (92.9)
Patients with related, temporally associated AEs (72 h), n (%) 7 (38.9) 2 (40.0) 20 (71.4)
Patients with serious AEs, n (%) 3 (16.7) 0 2 (7.1)
Patients discontinued due to AEs, n (%) 2 (11.1) 0 4 (14.3)
Patients discontinued due to related AEs, n (%) 0 0 3 (10.7)
AT all treated, N number of patients in age group, Ni number of infusions, AEs adverse events
758 J Clin Immunol (2011) 31:752–761events, rate 0.004 events per infusion), and psychomotor
hyperactivity (three events, rate 0.004 events per infusion).
Two related events of headache were reported in children
(rate 0.003 events per infusion). In adolescents, the only
related AE reported more than once was pruritus (three
events, rate 0.015 events per infusion). Adults experienced
more related AEs, which were neither local reactions nor
infections, the most frequent being headache (11 events,
rate 0.012 events per infusion), fatigue (five events, rate
0.005 events per infusion), and pruritus (five events, rate
0.005 events per infusion).
Almost all AEs, excluding local reactions, were mild or
moderate in intensity: 95.3% in children and 97.6% in
adolescents. Five patients experienced six severe AEs
(chest pain, C-reactive protein increased, appendicitis,
bronchitis, pneumonia, and cough). In adults, no severe
AEs were reported.
Serious Adverse Events and Adverse Events Leading
to Discontinuation
No deaths occurred during the study. Serious AEs and AEs
leading to discontinuation (all unrelated) were reported only
in children.
Three children (16.7%) experienced five SAEs, none of
them related to study medication. A 5-year-old girl with a
diagnosis of CVID experienced three SAEs: one event of
pyrexia and two events of X-ray proven pneumonia. The
first event of pneumonia, occurring in the wash-in/wash-out
period, was moderate in intensity and was considered an
SBI according to the pre-specified FDA criteria because
chest X-ray/CT scan showed distinctive nodular and new
infiltrative changes in both lungs, despite negative sputum
and blood cultures. Approximately a month later, when the
patient was hospitalized for diagnostic purposes, bronchoal-
veolar lavage was positive for atypical mycobacteria in
polymerase chain reaction test. Tests for Mycobacterium
tuberculosis were negative. With appropriate antibiotic
treatment, this SBI resolved after 34 days without sequelae.
Four days after Infusion 14, during the efficacy period, the
patient experienced pyrexia that was reported as an SAE of
moderate intensity; after treatment with antibiotics and
ibuprofen, the event resolved after 2 days without sequelae.
Four days after Infusion 22, the patient experienced
pneumonia that was reported as an SAE of severe intensity.
She had fever and cough, and her laboratory tests were
indicative of an ongoing inflammatory process (white blood
cells 25.69×10
9; C-reactive protein 31.8 mg/L; hemoglobin
9.7 g/dL; ALT 13.1 U/L). Because of the underlying lung
disease and medical history of recurrent pneumonia, this
event was an acute exacerbation of the existing pneumonia,
and thus not considered an additional SBI. The patient
completed the study as planned. Two other SAEs—diarrhea
(mild) experienced by a 7-year-old girl and appendicitis
(severe) experienced by a 10-year-old girl—resolved
without sequelae after 2 and 5 days, respectively.
After Infusion 2, an 8-year-old boy with XLA discon-
tinued because of myalgia, pyrexia, and nausea (moderate
intensity), and chest pain and C-reactive protein increased
(severe intensity). All these AEs were considered unrelated
to study medication and resolved without sequelae. The
patient was diagnosed with cystic lymphangioma, and
thoracic surgery was performed. A 5-year-old boy with
XLA discontinued because of anemia of moderate intensity
occurring after Infusion 32. The patient had suffered from
anemia for 1 year before entering the study and had low
hemoglobin values throughout the study (≤10.1 g/dL), as
well as abnormally low values for hematocrit, mean
corpuscular hemoglobin, mean corpuscular hemoglobin
concentration, and mean corpuscular volume at all measure-
ments. The AE was considered unrelated to study medication
and was ongoing at final assessment.
Laboratory Tests
Laboratory tests were unremarkable. Median values and
ranges of hematology and serum chemistry variables did not
show any relevant changes over time. Individual hematology,
blood chemistry, and urinalysis values lying outside the
normal range were considered by the investigator as not
clinically significant in all but two patients. A 10-year-old girl
with a history of anemia had low values for hemoglobin,
hematocrit, and mean corpuscular volume at most measure-
ments during the study. She was diagnosed with mild iron
deficiency anemia that was unrelated to study treatment and
resolved without sequelae after 95 days. The 5-year-old boy
who discontinued because of anemia had low values for
hematocrit, hemoglobin, and several other hematology tests
before Infusion 28 and at the completion visit, and a high
platelet count at the completion visit.
Discussion
This is the first report of Hizentra
® treatment in pediatric
patients with PI at doses equivalent to those in previous
therapy. Sustained IgG levels were achieved at equivalent
SCIG doses compared with previous IVIG or SCIG therapy,
and thus the primary objective of this study was met. A
statistically significant increase in IgG levels from baseline
was observed in children. Children and adolescents
responded well to therapy and even achieved greater
improvements in some endpoints compared with adults.
IgG trough levels achieved with equivalent doses were
similar to or higher than those with previous therapy,
suggesting that frequent subcutaneous administration con-
J Clin Immunol (2011) 31:752–761 759tributed to stabilization of serum IgG levels. In particular,
Hizentra
® treatment resulted in an increase of 22.4% in IgG
trough levels in children who had been previously treated
with equivalent IVIG doses. The mean IgG trough levels in
adolescents, most of whom had been treated with SCIG
previously, were maintained at levels between 6.2 and
9.5 g/L, which are considered sufficient for protection
against infections [24–26]. Similar IgG trough levels have
been published previously in pediatric patients treated with
IVIG or SCIG preparations. At monthly IgG doses of 200–
741 mg/kg, serum IgG trough concentrations of 5.68–
14.51 g/L in children and 8.2–13.9 g/L in adolescents were
reported in a study of Privigen
®, a 10% IVIG [9]. Mean IgG
trough levels achieved with Vivaglobin
®, a 16% SCIG, in
children aged 2–11 years, were 9.2 (±2.4) g/L [15]. IgG
trough levels obtained with other subcutaneous preparations
were similar (5.2–9.6 g/L [13]) or were reported to be in the
normal range [27, 28]. In a study of IVIG, 31 children with
agammaglobulinemia achieved serum IgG levels between 5
and 11.4 g/L [29]. Thus, Hizentra
® therapy normalized IgG
levels similarly in all patients, regardless of their age.
The overall efficacy, assessed by the rate of infections
and associated treatments, was similar in pediatric patients
and adults. Therefore, SCIG therapy can be used for the
treatment of PI from early childhood. The rates of all
infections, including SBIs, were similar in all age groups
and comparable to previously reported rates for IVIG or
SCIG treatments [9, 12, 30]. The number of days missed
from school, days spent in hospital, and days on antibiotics
was influenced markedly by the experience of the child
with recurrent pneumonia. The rates of these efficacy
endpoints in the other patients were within the range of
reported results [9, 12, 30–32].
An important observation in this study was that children
tolerated SCIG administration well, with no difference to
adolescents or adults. With respect to local reactions,
pediatric patients even showed better tolerability compared
to adults, with rates markedly lower than the rates observed
in adults. In our experience beyond the scope of this study,
the infusion of smaller volumes of the 20% SCIG yielded
better local tolerability compared to the available 16% and
16.5% SCIG preparations.
As SCIG therapy could help minimize the impact of
chronic disease on patients’ and families’ active lives
without compromising therapy, it is particularly suitable
for children. Only two children discontinued this study,
with none withdrawing consent, suggesting that self-
administration was accepted well. Because children need
lower infusion volumes to administer the required IgG
doses, Hizentra
® infusions were relatively short (in general,
less than an hour) and could be easily integrated in normal
daily routine, without a negative impact on patients’ quality
of life. This observation is in line with the results of
previous studies showing quality of life improvement in PI
children with SCIG therapy [33, 34]. Considering the
problematic venous access in young children, it is much
more practicable to use a subcutaneous way of administra-
tion in this age group. Therapy by the subcutaneous route
obviates also the use of premedication, which is an
additional benefit, as shown here and in previous studies
[15]. In addition, subcutaneous infusions are administered
with much smaller needles than intravenous infusions, and
the small pumps used could be comfortably carried on the
body if necessary. Frequent administration (two to seven
times a week) of small volumes is another option for
reducing the time for each infusion for more flexibility, and
may be a further option for patients as was shown in a
recent retrospective study [35]. Most importantly, SCIG
therapy offers a broad variety of administration options,
enabling each patient to find their preferred treatment
regimen. Children at school age are more active than
adults, and would feel better integrated in their environment
if they did not have to miss activities due to their therapy.
In conclusion, Hizentra
® is effective in maintaining or
increasing IgG trough levels and in protecting pediatric
patients from infections. No pediatric-specific dose require-
ment was necessary to achieve the desired serum IgG level.
Hizentra
® was well tolerated, with respect to both systemic
and local reactions. The short infusion duration and the lack
of severe local reactions favor self-administration, which
appears to be widely accepted by patents and their families.
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